Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a ...
There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.
Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...
Drugs such as Novo Nordisk’s Ozempic can cut drug and alcohol abuse by up to 50%, a study found, adding to mounting evidence ...
The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and ...
Britain will study whether the use of Eli Lilly's weight loss drug can get people back into work and help tackle the high ...
The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 ...
Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., ...
The FDA resolved the shortage of Eli Lilly's tirzepatide, but may revisit allowing compounding pharmacies to make copies, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback